These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 4325363)

  • 21. Duration of application and change of a regimen with secondary drugs.
    Oka S; Takase Y; Kato S
    Sci Rep Res Inst Tohoku Univ Med; 1968 Oct; 15(1):46-9. PubMed ID: 4308926
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmaceutical formulation of a fixed-dose anti-tuberculosis combination.
    Danckwerts MP; Ebrahim S; Pillay V
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):289-97. PubMed ID: 12661846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ethambytol in the retreatment of pulmonary tuberculosis. United States Public Health Service cooperative trial.
    Steininger WJ
    Bull Int Union Tuberc; 1968 Dec; 41():181-2. PubMed ID: 4303861
    [No Abstract]   [Full Text] [Related]  

  • 24. [Controlled trial of isoniazid.rifampicin.ethambutol regimen and isoniazid.rifampicin.pyrazinamide regimen in the primary chemotherapy for pulmonary tuberculosis (author's transl)].
    Kekkaku; 1980 Jan; 55(1):7-13. PubMed ID: 6988627
    [No Abstract]   [Full Text] [Related]  

  • 25. Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model.
    Pandey R; Khuller GK
    J Antimicrob Chemother; 2004 Jul; 54(1):266-8. PubMed ID: 15128731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral solid lipid nanoparticle-based antitubercular chemotherapy.
    Pandey R; Sharma S; Khuller GK
    Tuberculosis (Edinb); 2005; 85(5-6):415-20. PubMed ID: 16256437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Bactericidal therapy in patients with tuberculosis].
    Krasnov VA; Ursov IG
    Probl Tuberk Bolezn Legk; 2004; (3):21-6. PubMed ID: 15338895
    [No Abstract]   [Full Text] [Related]  

  • 28. Anti-tuberculosis 4FDC tablets--mystery to chemistry.
    Dekker TG; Lötter AP
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):205-6. PubMed ID: 12661831
    [No Abstract]   [Full Text] [Related]  

  • 29. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
    Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
    Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pilot studies on the treatment of Mycobacterium avium complex lung disease--new macrolides and new quinolones. (2) Multi-drug chemotherapy for initial cases on trial].
    Tanaka E
    Kekkaku; 1996 Sep; 71(9):547-9. PubMed ID: 8999140
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparative studies of various antituberculosis drug regimens by means of serum antimycobacterial activity tests in man.
    Hokama S
    Jpn J Tuberc; 1967 Jul; 14(1):55-65. PubMed ID: 5300098
    [No Abstract]   [Full Text] [Related]  

  • 32. Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential.
    Ahmad Z; Pandey R; Sharma S; Khuller GK
    Indian J Chest Dis Allied Sci; 2006; 48(3):171-6. PubMed ID: 18610673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparison of combination therapy of Capreomycin, ethionamide and cycloserin with that of kanamycin, ethionamide and cycloserin for the retreatment of pulmonary tuberculosis].
    Kitamoto O; Oka S; Kawamori Y; Gomi J; Sugiyama K
    Saishin Igaku; 1970 Jul; 25(7):1546-55. PubMed ID: 5451178
    [No Abstract]   [Full Text] [Related]  

  • 34. [Effect and toxicity on the combined use of pyrazinamide, ethionamide and kanamycin in the retreatment of pulmonary tuberculosis (author's transl)].
    Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi; 1979; 2(4):199-200. PubMed ID: 555425
    [No Abstract]   [Full Text] [Related]  

  • 35. [Effect of the addition of the 3rd agent on the combined therapy with ethionamide and kanamycin in tuberculosis in the mice].
    Matsumiya T; Freerksen E; Rosenfeld M
    Jpn J Tuberc Chest Dis; 1970 Jul; 16(1):30-4. PubMed ID: 4991617
    [No Abstract]   [Full Text] [Related]  

  • 36. [The experimental studies on antituberculous activity of lividomycin].
    Yamamoto K; Sakurai H; Inoue I; Yamagami K
    Kekkaku; 1972 May; 47(5):135-8. PubMed ID: 4339540
    [No Abstract]   [Full Text] [Related]  

  • 37. In reply.
    Reves RR
    Int J Tuberc Lung Dis; 2015 Apr; 19(4):495. PubMed ID: 25860012
    [No Abstract]   [Full Text] [Related]  

  • 38. [Therapeutic effect of rifampicin on re-treatment cases of pulmonary tuberculosis. The second study: a study on the combined therapy of rifampicin with ethambutol and pyrazinamide, especially on intermittent therapy].
    Kekkaku; 1972 Dec; 47(12):457-66. PubMed ID: 4652424
    [No Abstract]   [Full Text] [Related]  

  • 39. Experimental studies on the combined effect of kanamycin and viomycin.
    Hokama S
    Jpn J Tuberc Chest Dis; 1970 Jul; 16(1):62-9. PubMed ID: 4320009
    [No Abstract]   [Full Text] [Related]  

  • 40. Ethambutol in paediatric tuberculosis: aspects of ethambutol serum concentration, efficacy and toxicity in children.
    Thee S; Detjen A; Quarcoo D; Wahn U; Magdorf K
    Int J Tuberc Lung Dis; 2007 Sep; 11(9):965-71. PubMed ID: 17705973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.